Hennion & Walsh Asset Management, Inc.
Position in SPRY — ARS Pharmaceuticals, Inc.
CIK 1861642
Parsippany, NJ
Position in SPRY
as of Jun 30, 2026
· filed Jul 8, 2026
Position Value
$1,406,668
New position
Shares Held
175,614
first reported quarter
Ownership
0.177%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#3
of 22 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Hennion & Walsh Asset Management, Inc. holds $200,308,891 across 60 Biotechnology names. SPRY ranks #45 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JAZZ |
Jazz Pharmaceuticals plc
|
48,019 | $11,571,138 | |
| 2 | CELC |
Celcuity Inc.
|
100,368 | $10,500,500 | |
| 3 | URGN |
UroGen Pharma Ltd.
|
276,696 | $10,182,412 | |
| 4 | TVTX |
Travere Therapeutics, Inc.
|
171,470 | $9,741,210 | |
| 5 | SNDX |
Syndax Pharmaceuticals Inc
|
342,883 | $7,495,422 | |
| 6 | QURE |
uniQure N.V.
|
142,113 | $6,545,724 | |
| 7 | KURA |
Kura Oncology, Inc.
|
568,845 | $6,240,229 | |
| 8 | ARDX |
Ardelyx, Inc.
|
1,211,690 | $6,179,619 |
All Filings in SPRY
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,406,668 | 175,614 | Shares | Sole | 2026-07-08 | |
| No filing history on record for this holder in this stock. | ||||||